Nonproliferative retinopathy - Biotech, Pharma and Life Science Channel

10:11 EDT 4th August 2015 | BioPortfolio

PubMed Articles [288 Associated PubMed Articles listed on BioPortfolio]

Cytomegalovirus implicated in a case of progressive outer retinal necrosis (PORN).

Progressive outer retinal necrosis, also known as PORN, has been described as a variant of necrotizing herpetic retinopathy, occurring particularly in patients with acquired immune deficiency syndrome...

Re: Lepore et al.: Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings (Ophthalmology 2014;121:2212-9).

Re: Lepore et al.: Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings (Ophthalmology 2014;121:2212-9).

Abnormally Low or High Ankle-Brachial Index Is Associated with Proliferative Diabetic Retinopathy in Type 2 Diabetic Mellitus Patients.

Although some studies have reported that low ankle-brachial index (ABI) is associated with diabetic retinopathy (DR) in diabetic patients, it remains controversial as to which stage of DR. The aim of ...

FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy.

Diabetic retinopathy features inflammation as well as injury to glial cells and the microvasculature, which are influenced by hypertension and overactivity of the renin-angiotensin system. FT011 is an...

The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study.

Objectives To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, pl...

Potential for a paradigm change in the detection of retinopathy of prematurity requiring treatment.

SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: A Prospective Open-Label Study Using Canakinumab.

To evaluate the effect of systemic interleukin 1β inhibition using canakinumab (Ilaris) on retinal neovascularizations in proliferative diabetic retinopathy.

Elevated levels of peripheral blood CD14(bright) CD16(+) and CD14(dim) CD16(+) monocytes may contribute to the development of retinopathy in patients with juvenile onset type 1 diabetes.

The study aimed to analyze the CD14(bright) CD16(+) and CD14(dim) CD16(+) monocyte subsets in juvenile-onset complication-free diabetes mellitus type 1 in the context of their association with microva...

Blood Vessel Maturation by Disintegrin in Oxygen-Induced Retinopathy.

Although Arg-Gly-Asp (RGD) motif-containing disintegrins are associated with integrin inhibition and the activation of various biological processes, little is known about the role of RGD motif-contain...

News Articles [142 Associated News Articles listed on BioPortfolio]

ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc.

SAN FRANCISCO, July 30, 2015 /PRNewswire/ -- Global ENT (Ear, Nose, And Throat) devices market is expected to reach USD 23.01 million in 2022, according to a new study by Grand View Research, Inc. Gr...

Revised Draft v2.0 - Esperion (ESPR) Dives 20% in Response to Lackluster Label for PCSK9 Drug Approval

On Thursday, July 24, Praluent, a PCSK9 inhibitor from Regeneron / Sanofi was approved by the FDA. This was no surprise. We expected this drug to receive approval.It was approved for use in addition t...

Diabetic Retinopathy Market to Reach $10.11 Billion by 2022: Grand View Research, Inc.

SAN FRANCISCO, CA -- (Marketwired) -- 07/23/15 -- Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according to a new study by Grand View Research Inc. Diabetic reti...

Craniomaxillofacial (CMF) Devices Market to Reach $1.71 Billion By 2022: Grand View Research, Inc.

SAN FRANCISCO, July 22, 2015 /PRNewswire/ -- Global Craniomaxillofacial Devices Market is expected to reach USD 1.71 billion by 2022, according to a new study by Grand View Research, Inc. Increasing ...

Evaluating digital diabetic retinopathy screening in people aged 90 years and over

Evaluating digital diabetic retinopathy screening in people aged 90 years and over Eye advance online publication, July 17 2015. doi:10.1038/eye.2015.130 Authors: A Tye, H Wharton, A Wright...

Diabetic Retinopathy Market Worth $10.11 Billion By 2022: Grand View Research, Inc.

SAN FRANCISCO, July 16, 2015 /PRNewswire/ -- Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according to a new study by Grand View Research Inc. Diabetic retinopat...

Diabetic Retinopathy - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, Diabetic Retinopathy - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-05-28. This 180-page report is available ...

Allegro reports Phase II Luminate data in vitreoretinal disease

Allegro Ophthalmics LLC (San Juan Capistrano, Calif.) said the highest of three Luminate (ALG-1001) doses met the primary endpoint in a Phase II trial to treat vitreomacular traction (VMT) or vitreom...

Allegro Ophthalmics Announces Positive Topline Results from Phase 2 Trial Evaluating Luminate® in Patients with Vitreomacular Traction or Vitreomacular Adhesion

Study Meets Primary Efficacy Endpoint with 65% of Patients Treated with Luminate®Achieving VMT or VMA Release Allegro Ophthalmics, LLC, today announced that the Pha...

Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy

Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy Eye advance online publication, July 10 2015. doi:10.1038/eye.2015.114 ...

Events [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Acucela Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye di...

Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to de...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By...

NormOxys, Inc.

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen def...

Acucela

Acucela Inc. (www.acucela.com) is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for...

Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the ...

Clinical Trials [181 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)

The aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye drops in treating preterm newborns with a precocious stage of retinopathy of prematurity (ROP). ...

UK Surveillance of Treated Retinopathy of Prematurity

Currently, there is little recent data on regional variations in treatment methods, neonatal units that provide retinopathy (ROP) treatment, facilities for treatment available at each unit...

Omega-3 LCPUFA Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the ne...

Study of Topical Ocular PAN-90806 in PDR

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.

Analyses of Existing Framingham Data

Since 1948, the Framingham Study has examined a group of men and women every two years for the primary purpose of studying the incidence and prevalence of cardiovascular disease and its ri...

Study of Effectiveness of Telemedicine in Identifying Diabetic Retinopathy Cases

The aim of this study is to compare the effectiveness of identifying diabetic retinopathy using tele-medicine based Digital Retinal Imaging in Diabetes Clinics with that of the conventiona...

Prevalence of Peripheral Neuropathy in Children and Adolescents With Type I Diabetes Mellitus: a Prospective Study

Diabetes mellitus type I is an increasing burden for more and younger children. Therapy should avoid long-term complications as macrovascular diseases and diabetic nephropathy, retinopathy...

Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in patients with neo...

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial grow...

Analysis of Angiogenic Factor Levels in Eyes With Diabetic Retinopathy

This study was conducted to investigate the levels of angiogenic factors and anti-angiogenic factors in the aqueous humor of patients with diabetic retinopathy.

Videos

None available.

Medical and Biotech [MESH] Definitions

A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)

Degenerative changes to the RETINA due to HYPERTENSION.

A drug used to reduce hemorrhage in diabetic retinopathy.

Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.

Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.


Advertisement
 
Advertisement
 
review and buy Nonproliferative retinopathy market research data and corporate reports here

Channels Quicklinks